GSWM
ARQT icon

Golden State Wealth Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Golden State Wealth Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-59
Closed -$1.71K – 1619
2025
Q4 		$1.71K Hold
59
– – ﹤0.01% 1414
2025
Q3 		$1.11K Hold
59
– – ﹤0.01% 1492
2025
Q2 		$827 Hold
59
– – ﹤0.01% 1452
2025
Q1 		$923 Buy
+59
New +$831 ﹤0.01% 1434

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Golden State Wealth Management's ARQT Position: Q1 2026 in Review

Golden State Wealth Management sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 59 shares — an estimated $1.71K sold.

Golden State Wealth Management first reported a position in ARQT in Q1 2025 and held it in 4 quarters. The position peaked at $1.71K in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Golden State Wealth Management reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Golden State Wealth Management sold 59 Arcutis Biotherapeutics shares in Q1 2026, an estimated $1.71K.
  • Golden State Wealth Management first reported a position in Arcutis Biotherapeutics in Q1 2025 and held it in 4 quarters.
  • Golden State Wealth Management's Arcutis Biotherapeutics position peaked at $1.71K in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Golden State Wealth Management's 13F filing for Q1 2026, filed 28 Apr 2026.